×
DexCom Cash on Hand 2010-2024 | DXCM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
DexCom cash on hand for the quarter ending December 31, 2024 was
$2.579B
, a
5.31% decline
year-over-year.
DexCom cash on hand for 2024 was
$2.579B
, a
5.31% decline
from 2023.
DexCom cash on hand for 2023 was
$2.724B
, a
10.91% increase
from 2022.
DexCom cash on hand for 2022 was
$2.456B
, a
10.07% decline
from 2021.
View More
DexCom Cash on Hand 2010-2024 | DXCM
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
DexCom cash on hand for 2024 was
$2.579B
, a
5.31% decline
from 2023.
DexCom cash on hand for 2023 was
$2.724B
, a
10.91% increase
from 2022.
DexCom cash on hand for 2022 was
$2.456B
, a
10.07% decline
from 2021.
Related Stocks
Company Name
Market
Cap
Intuitive Surgical (ISRG)
$216B
Thermo Fisher Scientific (TMO)
$205.7B
Alcon (ALC)
$44.2B
Edwards Lifesciences (EW)
$44.1B
IDEXX Laboratories (IDXX)
$37.1B
IQVIA Holdings (IQV)
$34.2B
Mettler-Toledo (MTD)
$27.3B
Waters (WAT)
$22.6B
STERIS (STE)
$21.7B
SONOVA HOLDING (SONVY)
$19.3B
Hologic (HOLX)
$14.4B
Fresenius Medical Care AG KGaA (FMS)
$13.5B
Penumbra (PEN)
$11.7B
Sysmex ADR (SSMXY)
$11.5B
Globus Medical (GMED)
$11.5B
Masimo (MASI)
$9.5B
Glaukos (GKOS)
$8.7B
Teleflex (TFX)
$8.1B
Inari Medical (NARI)
$4.7B
Integer Holdings (ITGR)
$4.5B
PROCEPT BioRobotics (PRCT)
$3.4B
Veracyte (VCYT)
$3.2B
Nihon Kohden (NHNKY)
$2.7B
LivaNova (LIVN)
$2.6B
TransMedics (TMDX)
$2.5B
Elekta AB (EKTAY)
$2.3B
Tandem Diabetes Care (TNDM)
$2.1B
Integra LifeSciences Holdings (IART)
$1.7B
Alphatec Holdings (ATEC)
$1.5B
Pulse Biosciences (PLSE)
$1.2B